← Oncology Approval Tracker

FDA DECISION ·

Tukysa + trastuzumab + pertuzumab

tucatinib with trastuzumab and pertuzumab · Seagen / Pfizer

FDA approvalNew or expanded indicationBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Maintenance for adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment.

LAMPGEN ANALYSIS

Why it matters

This adds tucatinib to HER2-directed maintenance. The evidence applies to the handoff after induction, with eligibility in HER2CLIMB-05 requiring no progression after the induction regimen.

What research teams should watch

Document completed induction cycles, post-induction imaging and any brain metastases. That handoff determines whether maintenance evidence maps to an individual patient.

PRIMARY RECORDS

Sources